Article content continued
Sorenson said if clinical trials go well, the Providence vaccine could be ready for final Health Canada approval in early 2022. While many Canadians will already have been vaccinated by then, Sorenson said early delays in the vaccine rollout in both this province and across the country are evidence of the need for more vaccine from many additional producers.
“If you want to get life back to normal, you need to vaccinate about six billion people,” Sorenson said. “And we’ve seen distribution challenges in trying to vaccinate tens of millions of people. We need more capacity.”
Sorenson added that COVID-19 will be with us for the long haul, and will likely continue to mutate and appear as new and varied strains for years to come. He said a domestic vaccine that gives first priority to Canadians will be appealing to many.
“When there is another variant — and there will be another variant — we don’t want to be relying on two companies (Pfizer and Moderna) to manage that,” Sorenson said. “We (Providence) are more than happy to prioritize Canadians, and then go out and help whoever else we can help in the world.”